International sales outperformed expectations in Q1 due to reduced seasonality and the initial contribution of PFIC patients in global markets.The business model has reached financial self-sustainability, allowing the company to fund high-impact pipeline investments independently.Strategic expansion into PSC and hepatitis delta represents a move into larger adult patient populations, leveraging existing global commercial infrastructure.The acquisition of zolergosertib from Incyte establishes a second growth ...